Acumen Pharmaceuticals, Inc.
ABOS
We are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach targeting what we believe to be a key underlying cause of Alzheimer's disease, or AD. Alzheimer's disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$104M
▼ -18.6% YoY
Op. Margin
–
ROIC
-89.38%
▼ -27.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$88M
▼ -34.1% YoY
Op. Cash Flow (TTM)
-$88M
▼ -34.0% YoY
Net Debt
-$52M
Net Cash Position
Cash & Equiv.
$79M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ABOS
Held by ETFs
ABOS is in 2 US ETFs. The largest of them, with ABOS's weight in each:
Acumen Pharmaceuticals (ABOS) in two numbers
Questions about Acumen Pharmaceuticals
Does Acumen Pharmaceuticals (ABOS) pay a dividend?
No. Acumen Pharmaceuticals (ABOS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 21 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in ABOS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ABOS
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.